Drug Profile

RTA 1701

Alternative Names: RTA-1701

Latest Information Update: 27 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Reata Pharmaceuticals
Developer Biogen
Class Anti-inflammatories; Antifibrotics; Small molecules
Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Autoimmune disorders; Fibrosis; Inflammation

Most Recent Events

26 Sep 2023 Reata Pharmaceuticals has been acquired and merged into Biogen
28 Oct 2022 No recent reports of development identified for phase-I development in Fibrosis(In volunteers) in USA (PO)
28 Jul 2021 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Australia (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com